Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Issues associated with residual cell-substrate DNA in viral vaccines.

Sheng-Fowler L, Lewis AM Jr, Peden K.

Biologicals. 2009 Jun;37(3):190-5. doi: 10.1016/j.biologicals.2009.02.015. Epub 2009 Mar 14.

PMID:
19285882
2.

Viral vaccines and residual cellular DNA.

Horaud F.

Biologicals. 1995 Sep;23(3):225-8. Review.

PMID:
8527122
3.

An overview of cell DNA issues.

Petricciani J, Loewer J.

Dev Biol (Basel). 2001;106:275-82; discussion 317-29. Review.

PMID:
11761240
5.

Recent trends in cell substrate considerations for continuous cell lines.

Lubiniecki AS, Petricciani JC.

Curr Opin Biotechnol. 2001 Jun;12(3):317-9. Review.

PMID:
11404113
6.

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

Barrett PN, Mundt W, Kistner O, Howard MK.

Expert Rev Vaccines. 2009 May;8(5):607-18. doi: 10.1586/erv.09.19. Review.

PMID:
19397417
7.

An overview of animal cell substrates for biological products.

Petricciani J, Sheets R.

Biologicals. 2008 Nov;36(6):359-62. doi: 10.1016/j.biologicals.2008.06.004. Epub 2008 Jul 31. Review.

PMID:
18674929
8.

[Use of continuous human and animal cell lines for the production of viral vaccines].

Grachev VP, Khapchaev IuKh.

Zh Mikrobiol Epidemiol Immunobiol. 2008 Jan-Feb;(1):82-90. Review. Russian.

PMID:
18368760
9.

High hydrostatic pressure for development of vaccines.

Shearer AE, Kniel KE.

J Food Prot. 2009 Jul;72(7):1500-8. Review.

PMID:
19681278
10.

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.

Syrjänen KJ.

Scand J Infect Dis Suppl. 2009;107:3-32. doi: 10.1080/00365540902887730. Review.

PMID:
19408160
11.

Viral vectors in malaria vaccine development.

Limbach KJ, Richie TL.

Parasite Immunol. 2009 Sep;31(9):501-19. doi: 10.1111/j.1365-3024.2009.01141.x. Review.

12.

Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.

Global Advisory Committee on Vaccine Safety (GACVS); WHO secretariat.

Expert Rev Vaccines. 2009 Jun;8(6):705-16. doi: 10.1586/erv.09.40. Review.

PMID:
19485752
13.

SARS vaccines: where are we?

Roper RL, Rehm KE.

Expert Rev Vaccines. 2009 Jul;8(7):887-98. doi: 10.1586/erv.09.43. Review.

PMID:
19538115
14.

Quality-control issues and approaches in vaccine development.

Metz B, van den Dobbelsteen G, van Els C, van der Gun J, Levels L, van der Pol L, Rots N, Kersten G.

Expert Rev Vaccines. 2009 Feb;8(2):227-38. doi: 10.1586/14760584.8.2.227. Review.

PMID:
19196202
15.

Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).

Doroshenko A, Halperin SA.

Expert Rev Vaccines. 2009 Jun;8(6):679-88. doi: 10.1586/erv.09.31. Review.

PMID:
19485748
16.

Therapeutic human papillomavirus vaccination.

Albers AE, Kaufmann AM.

Public Health Genomics. 2009;12(5-6):331-42. doi: 10.1159/000214923. Epub 2009 Aug 11. Review.

PMID:
19684445
17.

Predictive models for carcinogenicity and mutagenicity: frameworks, state-of-the-art, and perspectives.

Benfenati E, Benigni R, Demarini DM, Helma C, Kirkland D, Martin TM, Mazzatorta P, Ouédraogo-Arras G, Richard AM, Schilter B, Schoonen WG, Snyder RD, Yang C.

J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Apr;27(2):57-90. doi: 10.1080/10590500902885593. Review.

PMID:
19412856
18.

Foot and mouth disease virus vaccines.

Rodriguez LL, Grubman MJ.

Vaccine. 2009 Nov 5;27 Suppl 4:D90-4. doi: 10.1016/j.vaccine.2009.08.039. Review.

PMID:
19837296
19.

Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome.

Voskens CJ, Strome SE, Sewell DA.

Curr Mol Med. 2009 Aug;9(6):683-93. Review.

PMID:
19689295
20.

DNA vaccines for the prevention and treatment of allergy.

Chua KY, Kuo IC, Huang CH.

Curr Opin Allergy Clin Immunol. 2009 Feb;9(1):50-4. doi: 10.1097/ACI.0b013e3283207ad8. Review.

PMID:
19532092

Supplemental Content

Support Center